These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24825983)

  • 81. 2D and 3D-QSAR analysis of pyrazole-thiazolinone derivatives as EGFR kinase inhibitors by CoMFA and CoMSIA.
    Pourbasheer E; Aalizadeh R; Shiri HM; Banaei A; Ganjali MR
    Curr Comput Aided Drug Des; 2015; 11(4):292-303. PubMed ID: 26548551
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Three-dimensional quantitative structure activity relationship (QSAR) of cytotoxic active 3,5-diaryl-4,5-dihydropyrazole analogs: a comparative molecular field analysis (CoMFA) revisited study.
    Hamad Elgazwy AS; Soliman DS; Atta-Allah SR; Ibrahim DA
    Chem Cent J; 2012 May; 6(1):50. PubMed ID: 22647291
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Structure-activity Relationship Study on Therapeutically Relevant EGFR Double Mutant Inhibitors.
    Fatima S; Agarwal SM
    Med Chem; 2020; 16(1):52-62. PubMed ID: 30727906
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 85. QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.
    Chauhan JS; Dhanda SK; Singla D; ; Agarwal SM; Raghava GP
    PLoS One; 2014; 9(7):e101079. PubMed ID: 24992720
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 87. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
    Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
    Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
    [TBL] [Abstract][Full Text] [Related]  

  • 89. 3D-QSAR, molecular dynamics simulations and molecular docking studies of benzoxazepine moiety as mTOR inhibitor for the treatment of lung cancer.
    Chaube U; Chhatbar D; Bhatt H
    Bioorg Med Chem Lett; 2016 Feb; 26(3):864-874. PubMed ID: 26764189
    [TBL] [Abstract][Full Text] [Related]  

  • 90. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
    Akhtar M; Bharatam PV
    Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Identification of potent EGFR inhibitors from TCM Database@Taiwan.
    Yang SC; Chang SS; Chen HY; Chen CY
    PLoS Comput Biol; 2011 Oct; 7(10):e1002189. PubMed ID: 22022246
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Novel variable selection quantitative structure--property relationship approach based on the k-nearest-neighbor principle.
    Zheng W; Tropsha A
    J Chem Inf Comput Sci; 2000 Jan; 40(1):185-94. PubMed ID: 10661566
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
    Sivan SK; Manga V
    J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Atom and receptor based 3D QSAR models for generating new conformations from pyrazolopyrimidine as IL-2 inducible tyrosine kinase inhibitors.
    Ul-Haq Z; Effendi JS; Ashraf S; Bkhaitan MM
    J Mol Graph Model; 2017 Jun; 74():379-395. PubMed ID: 28499271
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Assessment of Structural Basis for Thiazolopyridine Derivatives as DNA Gyrase-B Inhibitors.
    Zambre VP; Petkar NN; Dewoolkar VP; Bhadke SV; Sawant SD
    Curr Drug Discov Technol; 2023; 20(4):e220223213933. PubMed ID: 36815634
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
    Kolosenko I; Yu Y; Busker S; Dyczynski M; Liu J; Haraldsson M; Palm Apergi C; Helleday T; Tamm KP; Page BDG; Grander D
    PLoS One; 2017; 12(6):e0178844. PubMed ID: 28636670
    [TBL] [Abstract][Full Text] [Related]  

  • 97. 3d QSAR studies on a series of quinazoline derrivatives as tyrosine kinase (egfr) inhibitor: the k-nearest neighbor molecular field analysis approach.
    Noolvi MN; Patel HM
    J Basic Clin Pharm; 2010 Jun; 1(3):153-75. PubMed ID: 24825983
    [TBL] [Abstract][Full Text] [Related]  

  • 98. 3D-QSAR studies on fluroquinolones derivatives as inhibitors for tuberculosis.
    Bhattacharjee A; Mylliemngap BJ; Velmurugan D
    Bioinformation; 2012; 8(8):381-7. PubMed ID: 22570519
    [TBL] [Abstract][Full Text] [Related]  

  • 99. 3D QSAR study on substituted 1, 2, 4 triazole derivatives as anticancer agents by kNN MFA approach.
    Desai SP; Mohite SK; Alobid S; Saralaya MG; Patil AS; Das K; Almadani ME; Arif Hussain S; Hussain Alamer B; Abdulrahman Jibreel E; Ibrahim Almoteer A; Mohammed Basheeruddin Asdaq S
    Saudi Pharm J; 2023 Dec; 31(12):101836. PubMed ID: 38028224
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.